1 – 10 of 26
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
(2025) In International Journal of Cancer
- Contribution to journal › Article
- 2024
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Empowering macrophages : the cancer fighters within the tumour microenvironment in mantle cell lymphoma
- Contribution to journal › Article
- 2023
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
- Contribution to journal › Article
-
Mark
Secondary malignancies among mantle cell lymphoma patients
- Contribution to journal › Article
- 2022
-
Mark
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Tackling Mantle Cell Lymphoma in Europe
- Contribution to journal › Article
- 2021
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
- Contribution to journal › Article
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
- Contribution to journal › Article
